Patents Issued in September 30, 2014
  • Patent number: 8846042
    Abstract: The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: September 30, 2014
    Assignee: Fabion Pharmaceuticals, Inc.
    Inventor: Hongxing Zhou
  • Patent number: 8846043
    Abstract: A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: September 30, 2014
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Wangmao Ge, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Pia M. Challita-Eid
  • Patent number: 8846044
    Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: September 30, 2014
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Patent number: 8846045
    Abstract: The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: September 30, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Kristian Kjaergaard, Soeren Lund
  • Patent number: 8846046
    Abstract: A method of treating TNF? disorders is described, wherein the method comprises administering a low dose amount of a TNF? inhibitor.
    Type: Grant
    Filed: October 24, 2003
    Date of Patent: September 30, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Zehra Kaymakcalan, Robert Kamen
  • Patent number: 8846047
    Abstract: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.
    Type: Grant
    Filed: October 4, 2010
    Date of Patent: September 30, 2014
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Walter Newman, Shixin Qin, Theresa L. O'Keefe, Robert A. Obar
  • Patent number: 8846048
    Abstract: Biomarkers for predicting the severity of malaria and methods for their detection are disclosed. In one aspect, the present application discloses CXCL4, CXCL10, VEGF, PGDF, IL-1Ra, IL-8, MIP-1?, sFas, Fas-L, sTNF-R2, and sTNF-R1 as biomarkers for the severity of malaria. In another aspect, the present application discloses a method for determining the severity of malaria and predicting mortality due to cerebral malaria. The method comprises the detection of the biomarkers CXCL4 and/or CXCL10 and at least one more biomarker and determining the severity of malaria and predicting mortality due to cerebral malaria based upon the ratio of expression of the biomarkers in the subject versus the expression of the biomarkers in a control.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: September 30, 2014
    Assignee: Morehouse School of Medicine
    Inventors: Jonathan K. Stiles, James W. Lillard, Henry Benjamin Armatei Armah, Nana Otoo Wilson
  • Patent number: 8846049
    Abstract: The present application discloses an improved method for conducting saccharide—protein conjugation reactions using carbodiimide condensation chemistry. Depending on the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: September 30, 2014
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Leon Biemans, Pierre Duvivier
  • Patent number: 8846050
    Abstract: The present disclosure provides immunogenic compositions comprising the N-domain of carcinoembryonic antigen (CEA). These compositions are useful for inducing or enhancing an immune response, for inhibiting tumor cell growth and for treating cancer.
    Type: Grant
    Filed: May 11, 2011
    Date of Patent: September 30, 2014
    Assignee: Governing Council of the University of Toronto
    Inventors: Aws Abdul-Wahid, Jean Gariépy
  • Patent number: 8846051
    Abstract: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: September 30, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Olen M. Kew, Cara C. Burns, Jing Shaw, Raymond Campagnoli, Jacqueline Quay
  • Patent number: 8846052
    Abstract: A bacterial toxin protein such as a Shiga toxin protein is efficiently produced using plant cells. The plant cells are transformed using a DNA construct containing DNA encoding a hybrid protein in which the bacterial toxin proteins such as the Shiga toxin proteins are tandemly linked through a peptide having the following characteristics (A) and (B) to produce the bacterial toxin protein in the plant cells: (A) a number of amino acids is 12 to 30; and (B) a content of proline is 20 to 35%.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: September 30, 2014
    Assignees: Idemitsu Kosan Co., Ltd., National University Corporation Nara Institute of Science and Technology
    Inventors: Kazutoshi Sawada, Takeshi Matsui, Mayumi Yoshida, Nobuo Yoshida, Kyoko Yoshida
  • Patent number: 8846053
    Abstract: The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: September 30, 2014
    Assignee: SDG, Inc.
    Inventors: W. Blair Geho, John R. Lau
  • Patent number: 8846054
    Abstract: The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the prophylaxis and treatment of BVDV caused infections. The invention also relates to a method of vaccinating a pregnant cow.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: September 30, 2014
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Carol L. Rinehart, Craig Jones, Judy Myers-Kuhnhoff, Wayne Cole, William Charles Ohnesorge
  • Patent number: 8846055
    Abstract: Classical Swine Fever Virus (CSFV) E2 glycoprotein is a major inducer of neutralizing antibodies and protective immunity in swine. E2 mediates virus adsorption to the target cell, and harbors genetic determinants associated with virus virulence. CSFV E2 also contains between residues 829 and 837 a discrete epitope (TAVSPTTLR) recognized by monoclonal antibody (mAb) WH303, used to differentiate CSFV from related Pestiviruses Bovine Viral Diarrhea Virus (BVDV) and Border Disease Virus (BDV). In this report, a CSFV infectious clone of the virulent Brescia isolate (BICv) was used to progressively mutate the mAb WH303 epitope of CSFV E2 to the homologous amino acid sequence of BVDV strain NADL E2 (TSFNMDTLA).
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: September 30, 2014
    Assignee: The United States of America, as Represented by the Secretary of Agriculture
    Inventors: Manuel V. Borca, Guillermo R. Risatti
  • Patent number: 8846056
    Abstract: Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogues thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogues thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogues thereof.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: September 30, 2014
    Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control
    Inventors: Larry J. Anderson, Lia M. Haynes, Ralph A. Tripp
  • Patent number: 8846057
    Abstract: Previously we have identified a conserved domain (SAP, for SAF-A/B, Acinus, and PIAS) in the foot-and-mouth disease virus (FMDV) leader (L) protein coding region that is required for proper sub-cellular localization and function. Mutation of isoleucine 55 and leucine 58 to alanine (I55A, L58A) within the SAP domain resulted in a viable virus that displayed a mild attenuated phenotype in cell culture, along with altered sub-cellular distribution of L and failure to induce degradation of the transcription factor nuclear factor kappa-B. Here we report that inoculation of swine and cattle with this mutant virus results in the absence of clinical disease, the induction of a significant FMDV-specific neutralizing antibody response, and protection against subsequent homologous virus challenge. Remarkably, swine vaccinated with SAP mutant virus are protected against wild type virus challenge as early as two days post-vaccination suggesting that a strong innate as well as adaptive immunity is elicited.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: September 30, 2014
    Assignee: The United States of America, as Represented by the Secretary of Agriculture
    Inventors: Teresa B. De Los Santos, James J. Zhu, Fayna Diaz-San Segundo, Marvin J. Grubman, Marla J. Koster
  • Patent number: 8846058
    Abstract: A chimeric Shiga toxoid according to the invention contains an enzymatically-inactivated StxA subunit and a native StxB subunit. This hybrid Shiga toxoid induces the production of broadly cross-reactive species of antibodies against Shiga toxin following immunization. The StxA subunit is modified so that it is enzymatically inactive. The invention thus encompasses the Shiga toxoid or fragments thereof and the nucleic acid sequence of the Shiga toxoid or fragments thereof. The invention further encompasses the production of a Shiga toxoid, the production of antibodies using the Shiga toxoid and methods of productions, and an immunogenic composition containing the Shiga toxoid.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: September 30, 2014
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Michael J. Smith, Alison D. O'Brien, Louise D. Teel, Angela R. Melton-Celsa
  • Patent number: 8846059
    Abstract: Compositions suitable for use as ovarian cancer and/or tumor adjuvants in the preparation of ovarian cancer vaccines, particularly those vaccines useful in the treatment of human ovarian cancer, are provided. The ovarian cancer adjuvants described are comprised of an extracellular matrix material, such as small intestinal submucosal (SIS) tissue. The preparations may take the form of sheets, gels, liquids (injectable), tracer, or other solid or semi-solid preparation. Also disclosed are ovarian tumor inhibiting compositions that include extracellular matrix tissue adjuvants.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: September 30, 2014
    Assignee: University of Notre Dame
    Inventors: Mark A. Suckow, William Wolter
  • Patent number: 8846060
    Abstract: A matrix for tissue growth includes: (a) a first layer including a first assembly of collagen fibers; (b) a plurality of projections on a top surface of the first layer; and (c) a second layer bonded to a bottom portion of the first layer and including a second assembly of collagen fibers, wherein the second layer has a lower density than the first layer, and the matrix includes pores effective to support cell growth into the matrix. A method for providing the matrix is also described.
    Type: Grant
    Filed: January 12, 2007
    Date of Patent: September 30, 2014
    Assignee: Integra LifeSciences Corporation
    Inventors: Simon J. Archibald, Mark Spilker, Ronald T. Ingram, Jeffrey M. Brittan
  • Patent number: 8846061
    Abstract: Dietary vitamin-mineral supplements featuring various vitamins and minerals for benefiting individuals suffering from conditions such as nutritional deficiencies, vitamin deficiencies, aging, cancer, high blood pressure, high cholesterol, dementia, Alzheimer's disease, coronary artery disease, fatigue, and stroke. Vitamins and minerals may include Vitamin C, Vitamin A, pregnenolone, coenzyme Q10, Vitamin K2, acetyl L-carnitine arginate, L-glutathione, among others.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: September 30, 2014
    Inventor: Mark S. Bezzek
  • Patent number: 8846062
    Abstract: The invention relates to a reaction product of a polar modified polymer and an alkoxysilane having at least one solubilizing functional group and at least one amino substituent.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: September 30, 2014
    Assignee: L'Oreal
    Inventors: Hy Si Bui, Anita Chon Tong, Maria Pia Rossi
  • Patent number: 8846063
    Abstract: The present disclosure generally relates to a personal care composition containing a carrier, an oil phase having at least one terpene alcohol component, an at least partially fluorinated compound, and a stabilizer. In an exemplary aspect, the at least partially fluorinated compound is stable within the composition of the present disclosure with the introduction of an oil phase having at least one terpene alcohol component to stabilize the at least partially fluorinated compound. Thus, the composition provides an initial foaming action and longer term skin benefits provided by an oil phase contacting a terpene alcohol component. A stabilizing component may also be included to provide further stability to the composition.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: September 30, 2014
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Jeffery Richard Seidling, Sarah Anne Lemke, Scott W. Wenzel, Kroy Donald Johnson, Corey Thomas Cunningham
  • Patent number: 8846064
    Abstract: A cosmetic and pharmaceutical formulation for rejuvenation and restoration of the skin, and methods of making this formulation. The cosmetic and pharmaceutical formulations comprise liposomes containing partially acylated proteins with a modification level of 0.1 to 10% of their mass, wherein the proteins are present in the form of a supramolecular assembly.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: September 30, 2014
    Inventors: Artur Martynov, Boris S. Farber, Sonya Sophya Farber, Aleksandr Sitenko
  • Patent number: 8846065
    Abstract: The present invention is directed to a mixture of esters according to the general formula (I), R1—C(?O)—O—R2, wherein R1 is an alkyl moiety with 5 to 11 carbon atoms and wherein R2 is a an alkyl moiety with 8 to 18 carbon atoms and wherein the mixture comprises 10 or less than 10 weight-% of ester of the general formula (I) wherein R1 is an alkyl moiety with 9 or more carbon atoms, based on the total amount of esters according to formula (I). The invention is further directed to cosmetic and/or pharmaceutical compositions comprising such esters as well as to processes for the production of such esters.
    Type: Grant
    Filed: June 19, 2010
    Date of Patent: September 30, 2014
    Assignee: Cognis IP Management GmbH
    Inventors: Marc Beuché, Francois Canonville, Valerie Pian
  • Patent number: 8846066
    Abstract: Compositions and methods useful in the reduction of localized fat deposits and tightening of loose skin in subjects in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including, for example, lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: September 30, 2014
    Assignees: The Regents of the University of California, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Michael S. Kolodney, Adam M. Rotunda
  • Patent number: 8846067
    Abstract: Antimicrobial solutions and delivery systems for them use liquid antimicrobial solutions with: at least 80% of total weight of a carrier liquid comprising water, alcohol or a mixture of water and alcohol; at least 0.0001% by weight of the solution of I2; at least 0.0001% by weight of CuSO4; and sufficient acid in the solution top provide a pH of less than 7.0. A buffering system is also preferable in the solution, and the solution may be provided directly to wounds, burns or other skin damage as a liquid, as a spray or as a gel.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 30, 2014
    Inventors: Kenneth R. Code, Joseph Provenzano, Richard D. Bickerstaff
  • Patent number: 8846068
    Abstract: The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a polymer and a therapeutically effective amount of a local anesthetic or pharmaceutically acceptable salt thereof, wherein the drug depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the drug depot is capable of releasing (i) a bolus dose of the local anesthetic or pharmaceutically acceptable salt thereof at a site beneath the skin and (ii) a sustained release dose of an effective amount of the local anesthetic or pharmaceutically acceptable salt thereof over a period of at least 4 days.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: September 30, 2014
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Amira Wohabrebbi, William F. McKay, Vanja Margareta King, Danielle L. Biggs, Katara Shaw, Christopher M. Hobot, Phillip Edward McDonald
  • Patent number: 8846069
    Abstract: Coatings for an implantable medical device and a method of fabricating thereof are disclosed, the coatings comprising polymers of lactic acid.
    Type: Grant
    Filed: April 19, 2010
    Date of Patent: September 30, 2014
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Syed F.A. Hossainy, Yiwen Tang, Eugene T. Michal, Thierry Glauser, Stephen D. Pacetti, Jessica DesNoyer
  • Patent number: 8846070
    Abstract: A medical article is disclosed, comprising a biologically degradable AB block copolymer and a biologically degradable polymer that is capable, at equilibrium and at room temperature, of absorbing less than about 5 mass % water.
    Type: Grant
    Filed: July 29, 2008
    Date of Patent: September 30, 2014
    Assignee: Advanced Cardiovascular Systems, Inc.
    Inventors: Yiwen Tang, Syed F. A. Hossainy, Andrew C. Tung, Stephen D. Pacetti
  • Patent number: 8846071
    Abstract: A stent having a stent body made from a crosslinked bioabsorbable polymer is disclosed. A method of making the stent including exposing a tube formed from a bioabsorbable polymer to radiation to crosslink the bioabsorbable polymer and forming a stent body from the exposed tube is disclosed. The tube can include a crosslinking agent which induces crosslinking upon radiation exposure. Additionally or alternatively, the bioabsorbable polymer can be a copolymer that crosslinks upon exposure to radiation in the absence of a crosslinking agent.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: September 30, 2014
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventor: Lothar W. Kleiner
  • Patent number: 8846072
    Abstract: The present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided that include a first anesthetic and a second anesthetic. In such compositions, the second anesthetic is a solvent for the first anesthetic and provides an initial anesthetic effect upon administration to a subject. The non-polymeric carrier may optionally be a high viscosity liquid carrier material such as a suitable sugar ester. The compositions can further include one or more additional ingredients including active and inactive materials. Methods of using the compositions of the invention to produce a sustained anesthetic effect at a site in a subject are also provided.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: September 30, 2014
    Assignee: Durect Corporation
    Inventor: A. Neil Verity
  • Patent number: 8846073
    Abstract: Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: September 30, 2014
    Assignee: Allergan, Inc.
    Inventors: Lon T. Spada, James N. Chang, Michelle Luu
  • Patent number: 8846074
    Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: September 30, 2014
    Assignees: Cynapsus Therapeutics, Inc., ARx, LLC
    Inventors: Nathan John Bryson, Anthony John Giovinazzo, Scott David Barnhart, Michael Clinton Koons
  • Patent number: 8846075
    Abstract: The invention refers to a composition material that is intended for rapid transmucosal delivery in the mouth of a biologically active substance when in contact with saliva. The composition material comprises at least one ionic carbohydrate, having at least one biologically active substance ionically bound thereto, and at least one wetable non-soluble polymeric carbohydrate. The invention also refers to a method of preparing the composition material, which comprises the steps of: (a) providing a mixture of the at least one biologically active substance and at least one ionic carbohydrate in a solvent having a permissive pH for ionic bonding of the at least one biologically active substance to the at least one ionic carbohydrate; (b) mixing the mixture in the solvent for a period that is sufficient for allowing the ionic bonding to take place; and (c) recovering the mixture from the solvent.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: September 30, 2014
    Assignee: Magle Holding AB
    Inventors: Ingemar Jonsson, Hans Henrik Lidgard, Gustaf Plym Forshell
  • Patent number: 8846076
    Abstract: A hemostatic device for promoting the clotting of blood includes a gauze substrate, a clay material disposed on the gauze substrate, and also a polyol such as glycerol or the like disposed on the gauze substrate to bind the clay material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood emanating from the wound to cause the clotting. A bandage that can be applied to a bleeding wound to promote the clotting of blood includes a flexible substrate and a gauze substrate mounted thereon. The gauze substrate includes a clay material and a polyol. A hemostatic sponge also includes a gauze substrate and a dispersion of hemostatic material and a polyol on a first surface of the substrate.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: September 30, 2014
    Inventors: Raymond J. Huey, Denny Lo, Daniel J. Burns, Giacomo Basadonna, Francis X. Hursey
  • Patent number: 8846077
    Abstract: This application provides a high throughput method of making nanoparticles that utilizes plates comprising wells (e.g., 96-well plates).
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: September 30, 2014
    Assignee: Bind Biosciences, Inc.
    Inventor: David M. Dewitt
  • Patent number: 8846078
    Abstract: Brucellosis is a disease caused by facultative intracellular bacteria of the monospecific genus Brucella melitensis. The invention in one aspect is an immunogenic nucleic acid composition comprising DNA encoding Brucella melitensis Invasion Protein B, a polypeptide with at least 95% identity thereto, or an immunologically active fragment of either of these, and an adjuvant. In another aspect, the invention is a DNA vaccine composition comprising a plasmid vector having DNA encoding a polypeptide as recited above, in which said plasmid vector is adsorbed to a liposome. Other aspects of the invention include methods of inducing an enhanced immune response to Brucella infection in an animal, methods for the differential diagnosis in an animal of brucellosis and vaccination by an immunogenic nucleic acid composition having DNA encoding any of the above-recited polypeptides, and a kit for conducting said differential diagnosis methods.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: September 30, 2014
    Assignee: The Secretary of State for Environment, Food & Rural Affairs Acting through the Animal Health and Veterinary Laboratories Agency
    Inventors: Nicola Commander, Stephen Spencer
  • Patent number: 8846079
    Abstract: This invention comprises a sterically stabilized liposome carrier encapsulating a selected drug for the aerosol delivery of the drug effectual in the treatment of the lungs of a mammal, a composition containing the sterically stabilized liposome carrier and the selected drug effective for the treatment of the lungs of a mammal for asthma and inflammation of the lungs of the mammal as an aerosol and a method of, treatment using the composition. The composition provides effective treatment for the longer of a period of time at least twice as long as the selected drug alone or up to at least one week.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: September 30, 2014
    Assignee: VGSK Technologies, Inc.
    Inventors: Kameswari S. Konduri, Sandhya Nandedkar, Nejat Duzgunes, Ramakrishna Pattisapu
  • Patent number: 8846080
    Abstract: The present invention provides an immunogenic composition comprising at least one antigen delivery particle and at least one antigen, wherein the antigen and antigen delivery particle are linked using an intermediate linker.
    Type: Grant
    Filed: August 26, 2009
    Date of Patent: September 30, 2014
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Leon Biemans, Abdelatif Elouahabi
  • Patent number: 8846081
    Abstract: The present application relates to compositions comprising and methods of using a liposome comprising a pHLIP polypeptide, wherein a lipid bilayer of the liposome is substantially free of the pHLIP polypeptide.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: September 30, 2014
    Assignees: Rhode Island Board of Governors for Higher Education, Yale University
    Inventors: Yana K. Reshetnyak, Oleg A. Andreev, Donald M. Engelman
  • Patent number: 8846082
    Abstract: An encapsulation system is provided comprising nitrogen-purge, instant bonding encapsulation method. Specifically, the encapsulation system comprises a composition, a two-piece capsule comprising a capsule cap and a capsule body; a gas to purge oxygen from the composition within the capsule; and a sealing solution to seal the capsule cap to the capsule body. Associated methods for encapsulating compositions using the encapsulation system are also provided.
    Type: Grant
    Filed: March 21, 2006
    Date of Patent: September 30, 2014
    Assignee: Vita-Herb Nutriceuticals, Inc.
    Inventor: Bing Baksh
  • Patent number: 8846083
    Abstract: A process for local permucosal diffusion of amino acid salts of low dosage lipophlic non-steroidal anti-inflammatory or anti-mycotic molecules for an aqueous medicine for the treatment of bucco-pharyngeal ailments is disclosed. Compositions and tablets implementing this diffusion process are also disclosed.
    Type: Grant
    Filed: February 1, 2005
    Date of Patent: September 30, 2014
    Inventors: Philippe Perovitch, Marc Maury
  • Patent number: 8846084
    Abstract: The present invention relates to controlled release compositions of Zolpidem or pharmaceutically acceptable salts thereof adapted to release Zolpidem over a predetermined time period, according to a monophasic and/or a biphasic profile of dissolution. The present invention also relates to monolithic matrix based formulations of Zolpidem or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: September 30, 2014
    Assignee: Wockhardt Ltd
    Inventors: Prashant Manohar Mandaogade, Venkatesh Madhavacharya Joshi, Girish Kumar Jain
  • Patent number: 8846085
    Abstract: A directly tabletable ibuprofen formulation comprising a) 50-99% by weight of crystalline ibuprofen, b) 1-15% by weight of a finely divided excipient with a surface area of at least 100 m2/g, and c) 0-40% by weight of further excipients, with the proviso that the total amount of components a) to c) corresponds to 100% by weight, where at least 50% of the surface of the ibuprofen crystals are covered with the finely divided excipient.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: September 30, 2014
    Assignee: BASF SE
    Inventors: Kathrin Meyer-Boehm, Karl Kolter, Anisul Quadir
  • Patent number: 8846086
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: September 30, 2014
    Assignee: Purdue Pharma L.P.
    Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
  • Patent number: 8846087
    Abstract: The present invention relates to an enteric coating formulation, as well as methods for preparing and using said enteric coating formulation. In particular, the invention relates to an enteric coating formulation that is made up of foodeous approved materials.
    Type: Grant
    Filed: August 25, 2004
    Date of Patent: September 30, 2014
    Assignee: Sensient Colors LLC
    Inventor: Vic Young
  • Patent number: 8846088
    Abstract: A novel method for the preparation of a tablet comprising a calcium-containing compound, the method involves a melt granulation process by which a sugar alcohol is melted and embeds the calcium-containing compound so that a sufficient taste masking of the chalkiness is substantially achieved and an unpleasant mouth feel of the calcium-containing compound is substantially avoided, while at the same time obtaining a low tablet volume. The method of the invention is especially suitable for the manufacturing of tablets having a high load of a calcium-containing compound.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: September 30, 2014
    Assignee: Takeda Nycomed AS
    Inventors: Poul Egon Bertelsen, Peder Mohr Olsen, Carsten Martini Nielsen, Magnus Wilhelm Tolleshaug
  • Patent number: 8846089
    Abstract: A method is provided for producing a sugar-coated preparation including a solid composition containing a pharmacologically active ingredient and a sugar coating layer. The method comprises a step of forming the sugar coating layer with a sugar coating composition containing one or more sugar-alcohols selected from the group consisting of mannitol and erythritol and a polyvinyl alcohol-based resin. The sugar-coated preparation includes a solid composition containing a pharmacologically active ingredient and a sugar coating layer, wherein the sugar coating layer is made of a sugar coating composition containing one or more sugar-alcohols selected from the group consisting of mannitol and erythritol and a polyvinyl alcohol-based resin.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: September 30, 2014
    Assignee: Wakunaga Pharmaceutical Co., Ltd.
    Inventors: Yukoh Sakata, Masaharu Higuchi
  • Patent number: 8846090
    Abstract: The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: September 30, 2014
    Assignee: Euro-Celtique S.A.
    Inventors: Bianca Brögmann, Silke Muhlau, Christof Spitzley
  • Patent number: 8846091
    Abstract: The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: September 30, 2014
    Assignee: Euro-Celtique S.A.
    Inventors: Bianca Brögmann, Silke Mühlah, Christof Spitzley